Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ShangPharma has achieved the first milestone in its strategic partnership with Jiangsu Hengrui Medicine to develop novel therapeutic monoclonal antibodies.
Subscribe to our email newsletter
Both the companies have entered into a strategic partnership to deliver a drug candidate.
The long-term collaborative project includes three additional specific milestone targets.
Hengrui global R&D president Lianshan Zhang said that they have achieved the milestone just a few months into their strategic partnership with ShangPharma’s biologics division.
ShangPharma founder and CEO Michael Xin Hui said that reaching this strategically important milestone is just the first of many achievements that the relationship between ShangPharma and Hengrui will yield.